Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents-Reference-Cited by-同舟云学术

Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents

Published:2014-12-24 Issue:5 Volume:62 Page:883-889
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Ishida Hiroyuki¹²,Adachi Souichi³,Hasegawa Daiichiro⁴,Okamoto Yasuhiro⁵,Goto Hiroaki⁶,Inagaki Jiro⁷,Inoue Masami⁸,Koh Katsuyoshi⁹,Yabe Hiromasa¹⁰,Kawa Keisei¹¹,Kato Koji¹²,Atsuta Yoshiko¹³¹⁴,Kudo Kazuko¹⁵

Affiliation:

1. Department of Pediatrics; Kyoto Prefectural University of Medicine; Kyoto Japan

2. Division of Pediatrics; Matsushita Memorial Hospital; Moriguchi Japan

3. Human Health Sciences; Graduate School of Medicine; Kyoto University; Kyoto Japan

4. Department of Hematology and Oncology; Kobe Children's Hospital; Kobe Japan

5. Department of Pediatrics; Kagoshima University Graduate School of Medical and Dental Sciences; Kagoshima Japan

6. Department of Hematology; Kanagawa Children's Medical Center; Yokohama Japan

7. Department of Pediatrics; National Kyushu Cancer Center; Fukuoka Japan

8. Department of Hematology and Oncology; Osaka Medical Center and Research Institute for Maternal and Child Health; Izumi Japan

9. Department of Hematology/Oncology; Saitama Children's Medical Center; Saitama Japan

10. Department of Cell Transplantation; Tokai University Hospital; Isehara Japan

11. Osaka Medical Center and Research Institute for Maternal and Child Health; Izumi Japan

12. Department of Hematology and Oncology; Children's Medical Center; Japanese Red Cross Nagoya First Hospital; Nagoya Japan

13. Department of HSCT Data Management/Biostatistics; Nagoya University Graduate School of Medicine; Nagoya Japan

14. Japanese Data Center for Hematopoietic Cell Transplantation; Nagoya Japan

15. Division of Hematology and Oncology; Shizuoka Children's Hospital; Shizuoka Japan

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.25389/fullpdf

Reference31 articles.

1. Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: A report from the Childrens Oncology Group;Lange;Blood,2008

2. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: Results of AML-BFM 98;Creutzig;J Clin Oncol,2006

3. Risk stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese Childhood AML Cooperative Study Group;Tsukimoto;J Clin Oncol,2009

4. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials;Gibson;Leukemia,2005

5. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity;Shimoni;Leukemia,2006

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I‐BFM Study Group;British Journal of Haematology;2024-05-27

2. Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia;Cancers;2023-08-18

3. Photodynamic Stromal Depletion in Pancreatic Ductal Adenocarcinoma;Cancers;2023-08-16

4. Allogeneic Transplantation of Hematopoietic Stem Cells (HSCs) for Acute Leukemia in Children – Review of Literature and Experience of Single Center in Russia;Leukemia - From Biology to Clinic;2023-03-01

5. Myelodysplastic syndrome in a patient with Barth syndrome (3‐methylglutaconic aciduria type II);Pediatric Blood & Cancer;2022-10-02